Form 4: Cytokinetics CEO Sells Shares for Tax Obligations

Cytokinetics' President & CEO, Robert I. Blum, sold shares to cover tax withholding obligations from RSU vesting.

Summary

• Robert I. Blum, President & CEO and a Director of Cytokinetics Inc. (CYTK), reported two transactions.
• On March 17, 2026, Mr. Blum disposed of 12,673 shares of Common Stock at a price of $62.15 per share.
• On the same date, he disposed of an additional 23,928 shares of Common Stock, also at $62.15 per share.
• Both transactions were company-compelled sell-to-cover sales to satisfy tax withholding obligations related to RSU vesting.
• Following these transactions, Mr. Blum directly beneficially owns 430,330 shares of Common Stock.
• Additionally, 2,083 shares are indirectly held by The Bridget Blum 2003 Irrevocable Trust, and another 2,083 shares are indirectly held by The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Sell-to-cover transactions are routine and non-discretionary, primarily for tax purposes, and do not typically indicate a change in management's confidence or the company's operational performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions for tax obligations related to RSU vesting are a common and routine occurrence for executives in publicly traded companies. These are typically non-discretionary sales and do not necessarily reflect management's sentiment about the company's future prospects, unlike open market discretionary sales.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in company fundamentals or management's outlook.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sell-to-cover transaction by the CEO for tax obligations related to RSU vesting. It does not provide new information regarding the company's operational performance, strategic direction, or management's discretionary sentiment that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event is neutral to the investment thesis.

Keywords

CYTK, Cytokinetics, Form 4, Insider Transaction, Robert Blum, CEO, RSU Vesting, Stock Sale, Tax Withholding